| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 12
| Issue : 3 | Page : 529-533 |
|
|
Brain metastases in cancer patients attending a Gamma Knife Center: A study from a single institute in Iran
Parisa Azimi1, Sohrab Shahzadi1, Mohammad Ali Bitaraf2, Maziar Azar2, Mazdak Alikhani3, Alireza Zali1, Sohrab Sadeghi1, Ali Montazeri4
1 Department of Neurosurgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Neurosurgery, Tehran University of Medical Science, Tehran, Iran
3 Neurosurgeon, Iran Gamma Knife Center, Tehran, Iran
4 Mental Health Research Group, Health Metrics Research Centre, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran
Correspondence Address:
Parisa Azimi
Shohada Tajrish Hospital, Functional Neurosurgery Research Center of Shohada Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1793-5482.145564
|
|
|
Background: This study was aimed to explore data on brain metastases in cancer patients attending the Iranian Gamma Knife Center.
Meterials and Methods: This was a retrospective study. In all 5216 case records of patients who referred to the Iranian Gamma Knife Center for treatment of brain tumors during year 2003-2011 were reviewed. Data were explored to identify patients who developed brain metastases due to cancer and assessed the information as applied to cancer patients including survival analysis.
Results: Two hundred and twenty patients were identified as having brain metastases due to cancer. The mean age of patients was 54.0 (standard deviation [SD] =12.7) years. Patients were followed for an average of 7 months after treatment with gamma-knife. The median survival time for different the Graded Prognostic Assessment (GPA) was: GPA: 0-1, 4.0 ± 0.4 months; GPA: 1.5-2.5, 6.0 ± 0.7 months; GPA: 3, 9.0 ± 0.9 months; and GPA: 3.5-4.0, 12.0 ± 1.8 months and the overall median survival was 7.0 (SD = 0.6) months.
Conclusion: The findings suggest that many cancer patients in Iran might develop brain metastasis. Although, this is not a very high incidence compared with the existing statistics from other countries, there is an urgent need to explore the issue further.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
